results, and the agent is inexpensive. In 52% of the patients in whom thiazide diuretics were prescribed in the J-HOME study, the standard dose in Japan was employed (2 mg or more). The authors of the J-HOPE study propose the necessity of accurately describing the subsequent Guidelines for the Management of Hypertension (JSH 2004 ) and the sales promotion of low-dose thiazide in order to promote the prescription of low-dose thiazide diuretics.
The Board of Directors of the Japanese Society of Hypertension has submitted a proposal for promoting the sale of low-dose thiazide diuretics to the government. Simultaneously, it must be presented to many Japanese clinicians that the incidence of side effects related to administration of lowdose hypotensive diuretics is low. In this sense, the Diuretics in the Management of Essential Hypertension (DIME) study supported by the Japanese Society of Hypertension, an open label randomized control study regarding the safety of lowdose thiazide diuretics, that is, the initial onset of diabetes and other adverse metabolic reactions, should be accelerated (DIME trial: http://www.jpnsh.org/trial.html (Access Oct 30, 2006)).
For the widespread use of thiazide diuretics in Japan, lowdose thiazide diuretics acceptable for clinicians should be commercially available, and a low incidence of adverse reactions should be achieved.
